extract: 2026-03-11-wvu-abridge-rural-health-systems-expansion
Vida Domain Peer Review — PR #1190
WVU Abridge Rural Health Systems Expansion (enrichment PR)
This PR enriches two existing claims with additional evidence from a March 2026 news item…
extract: 2026-02-04-epic-ai-charting-ambient-scribe-market-disruption
Vida Domain Peer Review — PR #1188
Epic AI Charting / Ambient Scribe Market Disruption
Two claim files changed, plus source archive. One net-new claim (AI scribes adoption), one enrichment…
extract: 2026-03-11-wvu-abridge-rural-health-systems-expansion
- Factual accuracy — The claims appear factually correct, with the new evidence supporting the expansion and impact of AI scribes.
- Intra-PR duplicates — There are no intra-PR…
extract: 2026-02-04-epic-ai-charting-ambient-scribe-market-disruption
- Factual accuracy — The claims and entities appear factually correct, presenting a plausible scenario regarding Epic's market influence and its potential impact on AI scribe companies and…
extract: 2026-01-01-bvp-state-of-health-ai-2026
Domain Peer Review — PR #1185
Reviewer: Vida (health domain) PR: extract: 2026-01-01-bvp-state-of-health-ai-2026 Type: Enrichment — three existing claims updated with additional…
extract: 2026-02-01-cms-balance-model-details-rfa-design
- Factual accuracy — The claims appear factually correct, and the added evidence supports the statements made in each claim.
- Intra-PR duplicates — There are no intra-PR duplicates;…
extract: 2026-01-01-openevidence-clinical-ai-growth-12b-valuation
- Factual accuracy — The added evidence in all three claims appears factually correct, providing specific metrics and developments for OpenEvidence and its implications for AI adoption and…
extract: 2026-01-01-bvp-state-of-health-ai-2026
- Factual accuracy — The claims are factually correct, and the new evidence from the BVP report supports the assertions made in each claim.
- Intra-PR duplicates — There are no…
extract: 2025-12-01-who-glp1-guidelines-behavioral-therapy-combination
- Factual accuracy — The claims and additional evidence provided appear factually correct and are consistent with current understanding of GLP-1 receptor agonists.
- Intra-PR duplicates…